Rigor Reviewed

Rigor-Reviewed Manuscript

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

Name: Αlpha¹ Rigor Record — Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
Item: Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
Rating: 59
Author: Αlpha¹

Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, Scott R, Stroes ESG, Froman S, Mendizabal G, Wang F, Catapano AL

Paper source

Read full text (PMC)PDF

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.5★ (Adequate), 0 critical, 5 high issues for “Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingEthical approvals partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed

Reporting gaps2

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed
Ethics/consent reporting incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 3 randomized controlled trial with a clear premise, rigorous design, and appropriate statistical analysis. The main weaknesses are missing explicit ethics approval and informed consent statements, an incomplete data sharing statement, and a few minor reporting gaps (e.g., statistical software, randomization method, power analysis).

Both reviewers classified the study as interventional, and I adopt that classification. The evaluation covered the abstract and methods/results sections; some details (e.g., full data sharing statement, ethics approval) were not available in the provided text. The statistics verification checked 5 reported tests, all consistent, but this does not confirm the entire statistical analysis.

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Recomputed 5 tests: 5 consistent, 0 inconsistent; 5 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions6 pass · 2 warn

The introduction cites the increased cardiovascular risk in HeFH and the failure of many patients to achieve LDL-C goals with current therapies, establishing the need for new treatments. The objective directly follows from this premise. The paper does not explicitly discuss limitations of prior research, but the premise is well-supported.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing the unmet need in HeFH and prior research on PCSK9 inhibitors, and provides a logical rationale for the study.

Evidence

direct quote[Introduction (Importance)]

“Many patients with HeFH do not achieve guideline-recommended LDL-C goals with the currently available lipid-lowering therapies.”

direct quote[Introduction (Objective)]

“To evaluate the efficacy of enlicitide decanoate (an oral proprotein convertase subtilisin/kexin type 9 inhibitor) vs placebo in adults with HeFH requiring further lowering of LDL-C levels despite use of statin therapy.”

absence[Introduction]

Limitations of prior research are not explicitly discussed.

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise: HeFH patients have elevated LDL-C and many do not achieve goals with current therapies, justifying evaluation of a new oral PCSK9 inhibitor.

Evidence

direct quote[Introduction (Importance)]

“Persons with heterozygous familial hypercholesterolemia (HeFH) are at increased risk of atherosclerotic cardiovascular disease due to lifelong elevated levels of low-density lipoprotein cholesterol (LDL-C). Many patients with HeFH do not achieve guideline-recommended LDL-C goals with the currently available lipid-lowering therapies.”

direct quote[Introduction (Objective)]

absence[Introduction]

Limitations of prior research are not explicitly discussed.

Randomization method is not explicitly described (e.g., computer-generated), but the trial is described as randomized and double-blind. The unit of randomization is the participant. Blinding is stated (double-blind). A power analysis is not reported, but the sample size is large and the effect size is large. Inclusion/exclusion criteria are clearly defined. The analysis population (modified intention-to-treat) is described, addressing missing data. The placebo control is appropriate.

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, double-blind, placebo-controlled, with a pre-specified primary endpoint and appropriate statistical analysis.

Evidence

direct quote[Abstract (Design)]

“This phase 3, randomized clinical trial”

direct quote[Methods (Design, Setting, and Participants)]

“included persons aged 18 years or older with HeFH currently using lipid-lowering therapy (taking at least a moderate- or high-intensity statin) and either an LDL-C level of 55 mg/dL or greater and a history of major atherosclerotic cardiovascular disease or an LDL-C level of 70 mg/dL or greater without a history of major atherosclerotic cardiovascular disease.”

direct quote[Methods (Main Outcomes and Measures)]

“The primary outcome was the mean percentage change in LDL-C level at week 24.”

PASSReviewer 2· 95% conf

The trial is well-designed: randomized, double-blind, placebo-controlled, with a pre-specified primary outcome and adequate sample size.

Evidence

direct quote[Abstract (Design, Setting, and Participants)]

“This phase 3, randomized clinical trial included persons aged 18 years or older with HeFH currently using lipid-lowering therapy (taking at least a moderate- or high-intensity statin) and either an LDL-C level of 55 mg/dL or greater and a history of major atherosclerotic cardiovascular disease or an LDL-C level of 70 mg/dL or greater without a history of major atherosclerotic cardiovascular disease.”

direct quote[Methods (Interventions)]

“Participants were randomized (2:1) to 20 mg of enlicitide (n = 202) or placebo (n = 101) once daily for 52 weeks.”

absence[Methods]

Power analysis is not reported.

The paper reports mean age, sex distribution, and baseline LDL-C levels. It does not report race/ethnicity or comorbidities in the abstract, but these are likely in the full results. Since both sexes are enrolled, sex justification is not applicable.

Sub-criteria

demographicsINADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline characteristics are reported, including age, sex, and lipid levels.

Evidence

direct quote[Abstract (Results)]

“mean age, 52.4 [SD, 13.5] years; 51% were female”

direct quote[Abstract (Results)]

“The mean LDL-C level was 119.0 mg/dL (SD, 41.0 mg/dL) at baseline”

absence[Abstract]

Race/ethnicity and comorbidities are not reported in the abstract.

PASSReviewer 2· 90% conf

Key biological variables (sex, age, baseline LDL-C) are reported; demographics are adequate for a human trial.

Evidence

direct quote[Results (first paragraph)]

“Of the 303 participants (mean age, 52.4 [SD, 13.5] years; 51% were female) randomized, 293 (96.7%) completed the trial.”

direct quote[Results (first paragraph)]

“The mean LDL-C level was 119.0 mg/dL (SD, 41.0 mg/dL) at baseline, all had statin current use (81.5% were taking a high-intensity statin), and 64.4% were taking ezetimibe.”

The paper is a clinical trial involving human participants, so ethics approval and informed consent are required. The abstract and methods do not mention an IRB or ethics committee approval, nor informed consent. The trial registration number is provided, which implies ethical oversight, but the explicit statement is missing.

Sub-criteria

iacuc statementN/A

informed consentNOT REPORTED

irb ethics statementNOT REPORTED

regulatory complianceNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

The paper does not explicitly state ethics approval or informed consent, which is a reporting gap for a clinical trial.

Evidence

absence[Full text]

No ethics approval statement is present.

absence[Full text]

No informed consent statement is present.

direct quote[Abstract (Trial Registration)]

“ClinicalTrials.gov Identifier: NCT05952869”

WARNReviewer 2· 80% conf

The paper does not explicitly state ethics approval or informed consent, which is a reporting gap for a human trial.

Evidence

absence[Full text]

No ethics approval statement is present.

absence[Full text]

No informed consent statement is present.

The drug enlicitide decanoate is named, and the dose (20 mg) is given. The manufacturer is implied (Merck). However, the formulation and lot numbers are not provided, which is typical for a clinical trial. No other biological resources are used.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational drug (enlicitide) is identified, and the trial is a drug trial, so the drug is the key resource.

Evidence

direct quote[Methods (Interventions)]

“Participants were randomized (2:1) to 20 mg of enlicitide (n = 202) or placebo (n = 101) once daily for 52 weeks.”

absence[Methods]

Statistical software is not identified.

PASSReviewer 2· 85% conf

The investigational product (enlicitide) is identified, and the trial is scored on that basis.

Evidence

direct quote[Methods (Interventions)]

“Participants were randomized (2:1) to 20 mg of enlicitide (n = 202) or placebo (n = 101) once daily for 52 weeks.”

absence[Methods]

Statistical software is not identified.

The primary analysis uses a mixed model for repeated measures, which is appropriate. Tests are not explicitly named but the model is described. Exact p-values are reported (P < .001). Effect sizes with 95% CIs are reported. Statistical software is not identified. Data presentation includes per-group n and CIs. Mathematical plausibility is not applicable due to large N and continuous outcomes.

Sub-criteria

tests namedINADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and results are reported with confidence intervals and p-values.

Evidence

direct quote[Abstract (Results)]

“between-group difference, −59.4% [95% CI, −65.6% to −53.2%]; P < .001”

absence[Methods]

Statistical software is not identified.

PASSReviewer 2· 90% conf

Statistical tests are named, effect sizes with CIs are reported, and p-values are exact. The analysis is appropriate for a clinical trial.

Evidence

direct quote[Results (second paragraph)]

“The mean percentage change in LDL-C level at week 24 was −58.2% in the enlicitide group vs 2.6% in the placebo group (between-group difference, −59.4% [95% CI, −65.6% to −53.2%]; P < .001).”

absence[Methods]

Statistical software is not identified.

The paper mentions a 'Data Sharing Statement: See .' but the actual statement is not included in the provided text. This is vague and does not specify a concrete access route. No data repository or code repository is mentioned.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

A data sharing statement is mentioned but not detailed; no repository or accession numbers are provided.

Evidence

direct quote[Article Information]

“Data Sharing Statement: See .”

absence[Full text]

No repository deposit is mentioned.

WARNReviewer 2· 80% conf

A data sharing statement is mentioned but not detailed; no repository or accession numbers are provided.

Evidence

direct quote[Article Information (Data Sharing Statement)]

“Data Sharing Statement: See .”

The trial is registered with ClinicalTrials.gov. Methods are described in sufficient detail. The reporting guideline (CONSORT) is not explicitly mentioned, but the paper follows standard reporting. All outcomes are reported. Limitations are not explicitly discussed in the abstract, but likely in the full text. Conclusions are proportional. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedNOT REPORTED

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are described, and conclusions are proportional to the results.

Evidence

direct quote[Abstract (Trial Registration)]

“ClinicalTrials.gov Identifier: NCT05952869”

paraphrase[Article Information]

“Funding/Support: Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc.”

absence[Abstract]

Limitations are not discussed in the abstract.

PASSReviewer 2· 90% conf

The trial is registered, methods are complete, and conclusions are proportional. Limitations are not explicitly discussed, but the paper is otherwise transparent.

Evidence

direct quote[Abstract (Trial Registration)]

“Trial Registration ClinicalTrials.gov Identifier: NCT05952869”

paraphrase[Article Information (Funding/Support and Conflict of Interest Disclosures)]

“Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc.”

3 copyedit issues flagged: mostly consistency, clarity.

Checked 1 reference by DOI: 1 verified.

Reproducibility

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Αlpha¹ Rigor Action ItemsFinal pass before journal submission

The published work is robust overall, but an informed reader should weigh the missing explicit ethics approval and informed consent statements, and the incomplete data sharing statement. These are reporting gaps that could warrant a correction or clarification from the authors, but they do not undermine the validity of the trial results.

1.
HIGHethics
Add an explicit ethics approval statement in the Methods section, naming the IRB/ethics committee and approval number, and a statement on informed consent.
A clinical trial must document ethics approval and informed consent; its absence is a serious reporting gap that could trigger a correction.
2.
HIGHdata code
Provide the full data sharing statement in the manuscript, specifying how to access the data (e.g., via a data-sharing platform or on request with conditions).
The current statement is incomplete ('See .'), which fails to meet transparency requirements for a data-driven trial.
3.
HIGHreporting
Add a limitations section in the Discussion, addressing potential biases, generalizability, and missing data handling.
Limitations are not explicitly discussed, which is expected in a clinical trial report and helps readers interpret the findings.
4.
HIGHstatistics
Identify the statistical software used for analysis (e.g., SAS version) in the Methods.
Reporting the software is a standard requirement for reproducibility.
5.
HIGHreporting
Mention adherence to CONSORT reporting guidelines in the Methods or as a footnote.
Explicitly stating CONSORT adherence is expected for randomized trials.
6.
MEDIUMrigor
Describe the randomization method (e.g., computer-generated random sequence) and allocation concealment in the Methods.
The randomization method is not described, which is a minor but important methodological detail.
7.
MEDIUMrigor
Report the power analysis or sample size calculation in the Methods to justify the sample size.
A power analysis is not reported, which is a common expectation for clinical trials.
8.
MEDIUMstatistics
Include a statement on how outliers or missing data were handled in the statistical analysis.
Outlier handling is not explicitly described, which is a minor reporting gap.
9.
LOWcopyedit
Clarify the sentence in the Abstract about trial conduct: 'The trial was conducted at 59 sites across 17 countries; the first participant was screened on August 8, 2023, and the last follow-up visit occurred on April 7, 2025.'
Minor style issue for clarity.

Full text (10,156 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside